Assenagon Asset Management S.A. Purchases 201,642 Shares of Merck & Co., Inc. $MRK

Assenagon Asset Management S.A. raised its position in Merck & Co., Inc. (NYSE:MRK) by 37.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 743,214 shares of the company’s stock after purchasing an additional 201,642 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Merck & Co., Inc. were worth $89,401,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Kingdom Financial Group LLC. acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $25,000. Abound Financial LLC acquired a new position in Merck & Co., Inc. during the fourth quarter worth $26,000. Prosperity Bancshares Inc acquired a new position in Merck & Co., Inc. during the fourth quarter worth $26,000. United Financial Planning Group LLC bought a new stake in Merck & Co., Inc. during the third quarter worth $31,000. Finally, High Note Wealth LLC raised its position in Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s tulisokibart met its endpoint in a Phase 3 ulcerative colitis study, strengthening confidence in the company’s immunology pipeline and offering a possible future growth driver. Merck’s Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study
• Positive Sentiment: The European Commission approved Keytruda in combination with Padcev for cisplatin-ineligible patients with resectable muscle-invasive bladder cancer, which could support oncology sales and broaden Keytruda’s international use. European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev®
• Positive Sentiment: CICC Research initiated coverage on Merck with an outperform rating and a $138 price target, signaling Wall Street expects further upside from current levels. Benzinga report on CICC coverage
• Neutral Sentiment: Citi maintained its hold rating on Merck, suggesting a more cautious view but no major change in the stock thesis. Citi Keeps Their Hold Rating on Merck & Company (MRK)
• Positive Sentiment: Scotiabank reaffirmed its buy rating on Merck, adding to the bullish analyst backdrop. Scotiabank Reaffirms Their Buy Rating on Merck & Company (MRK)

Analyst Ratings Changes

A number of brokerages have recently commented on MRK. Weiss Ratings downgraded shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Citigroup started coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price on the stock. UBS Group raised their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, April 13th. CICC Research initiated coverage on Merck & Co., Inc. in a report on Wednesday. They set an “outperform” rating and a $138.00 price target for the company. Finally, Wells Fargo & Company lowered their price target on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $128.72.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $120.74 on Thursday. The company has a market capitalization of $298.21 billion, a price-to-earnings ratio of 34.01, a PEG ratio of 2.69 and a beta of 0.21. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The company has a 50-day simple moving average of $115.77 and a 200 day simple moving average of $114.05. Merck & Co., Inc. has a 52 week low of $76.66 and a 52 week high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. The firm had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business’s revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the firm earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, sell-side analysts predict that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.85 per share. The ex-dividend date is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.